2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1338A
    PL-017 TFA 98%
    PL-017 TFA is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats.
    PL-017 TFA
  • HY-P1340A
    [Ala11,D-Leu15]-Orexin B(human) TFA 98%
    [Ala11,D-Leu15]-Orexin B(human) TFA is a potent and selective orexin-2 receptor (OX2) agonist. [Ala11,D-Leu15]-Orexin B(human) TFA shows a 400-fold selectivity for the OX2 (EC50=0.13 nM) over OX1 (52 nM).
    [Ala11,D-Leu15]-Orexin B(human) TFA
  • HY-P1341A
    OXA(17-33) TFA 98%
    OXA(17-33) TFA is a potent and selective orexin-1 receptor (OX1) agonist. OXA(17-33) TFA shows a ∼23-fold selectivity for the OX1 (EC50=8.29 nM) over OX2 (187 nM).
    OXA(17-33) TFA
  • HY-P1342A
    Prosaptide Tx14(A) TFA 98%
    Prosaptide Tx14(A) TFA, a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC50s of 5 and 7 nM, respectively. Prosaptide Tx14(A) TFA increases both ERK1 and ERK2 phosphorylation in Schwann cells.
    Prosaptide Tx14(A) TFA
  • HY-P1363S
    β-Amyloid-15N (1-42), human TFA 98%
    β-Amyloid-15N (1-42), human (TFA) is the 15N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
    β-Amyloid-15N (1-42), human TFA
  • HY-P1369A
    DynaMin inhibitory peptide, myristoylated TFA 98%
    DynaMin inhibitory peptide, myristoylated TFA is a DynaMin inhibitor to interfere with the binding of amphiphysin with dynamin. DynaMin inhibitory peptide, myristoylated TFA is a membrane-permeant form of the peptide that prevents endocytosis.
    DynaMin inhibitory peptide, myristoylated TFA
  • HY-P1378A
    β-Amyloid (1-43)(human) TFA 98%
    β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use.
    β-Amyloid (1-43)(human) TFA
  • HY-P1379A
    C14TKL-1 acetate 98%
    C14TKL-1 acetate is the acetate salt form of C14TKL-1 (HY-P1379). C14TKL-1 acetate is a tachykinin-like peptide and exhibits an agonistic activity for neurokinin receptor 1 (NK-1).
    C14TKL-1 acetate
  • HY-P1389A
    Neuropeptide S (human) TFA 98%
    Neuropeptide S human TFA, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human TFA can be used for Alzheimer's disease (AD) research.
    Neuropeptide S (human) TFA
  • HY-P1437A
    Neuropeptide S(Mouse) TFA 98%
    Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC50=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca2+. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.
    Neuropeptide S(Mouse) TFA
  • HY-P1438A
    Neuropeptide S(Rat) TFA 98%
    Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC50=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.
    Neuropeptide S(Rat) TFA
  • HY-P1440A
    BeKm-1 TFA 98%
    BeKm-1 TFA is a potent and selective KV11.1 (hERG) channel blocker. BeKm-1 TFA is selective for KV11.1 over a panel of 14 other potassium channels. BeKm-1 TFA dose-dependently prolongs QTc interval in isolated rabbit heart.
    BeKm-1 TFA
  • HY-P1502F
    Biocytin-β-endorphin, human 98%
    Biocytin-β-endorphin, human is abiotinylated β-Endorphin, human (HY-P1502). β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.
    Biocytin-β-endorphin, human
  • HY-P1775A
    Carbonic anhydrase (isoenzyme) 9001-03-0
    Carbonic anhydrase isoenzyme is the isoenzyme of Carbonic anhydrase (HY-P1775). Carbonic anhydrase isoenzyme is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase isoenzyme catalyzes reversible conversion of carbon dioxide to bicarbonate and protons, and can be used for the research of cancer, glaucoma, obesity and epilepsy.
    Carbonic anhydrase (isoenzyme)
  • HY-P1840A
    Galanin Receptor Ligand M35 TFA 98%
    Galanin Receptor Ligand M35 TFA is a high-affinity ligand and antagonist of galanin receptor (Kd=0.1 nM). Galanin Receptor Ligand M35 TFA exerts a Ki values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.
    Galanin Receptor Ligand M35 TFA
  • HY-P1906A
    [pThr3]-CDK5 Substrate TFA 98%
    [pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM.
    [pThr3]-CDK5 Substrate TFA
  • HY-P2155A
    BigLEN(rat) TFA 98%
    BigLEN(rat) is a potent GPR171 agonist with an EC50 of 1.6 nM.
    BigLEN(rat) TFA
  • HY-P2210A
    BigLEN(mouse) TFA 98%
    BigLEN(mouse) TFA is a GPR171 agonist. BigLEN(mouse) TFA is a proSAAS-derived neuropeptide. BigLEN(mouse) TFA regulates food intake in mice. BigLEN(mouse) inhibits the release of glutamate onto parvocellular neurons of the paraventricular nucleus in a process dependent upon activation of postsynaptic G proteins.
    BigLEN(mouse) TFA
  • HY-P2243A
    D-JBD19 TFA 98%
    D-JBD19 TFA is a non-permeable peptide. D-JBD19 TFA has neuroprotective effects.
    D-JBD19 TFA
  • HY-P2277A
    PEN (rat) (TFA) 98%
    PEN (rat) TFA, one of the most abundant hypothalamic neuropeptide and derived from the proprotein ProSAAS, is an endogenous ligand of GPR83.
    PEN (rat) (TFA)
Cat. No. Product Name / Synonyms Application Reactivity